et al . et al . et al . et al . et al . et al . et al . et al . et al . et al . et al . et al . et al . et al . et al . et al . et al . et al .
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
EDITORIAL

For debate: that Australia should consider changing to the bivalent vaccine

Peter L. Stern

CR UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK. Email: pstern@picr.man.ac.uk

Sexual Health 7(3) 238-241 https://doi.org/10.1071/SH09131
Submitted: 1 December 2009  Accepted: 28 January 2010   Published: 19 August 2010


References


[1] Cervarix®. Summary of Product Characteristics. Uxbridge: GSK; 2009. Available online at: http://emc.medicines.org.uk/medicine/20204/SPC/Cervarix/#PRODUCTINFO [verified February 2010].

[2] Gardasil®. Summary of Product Characteristics. Whitehouse Station: Merck; 2009. Available online at: http://www.gardasil.com/ [verified February 2010] .

[3] Stanley M,  Lowy DR,  Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24(Suppl 3): S106–113.
CrossRef |

[4] Kim JJ,  Brisson M,  Edmunds WJ,  Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008; 26(Suppl 10): K76–86.
CrossRef | PubMed |

[5] Kim JJ,  Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339 b3884.
CrossRef | PubMed |

[6] Brotherton JM,  Heywood A,  Heley S. The incidence of genital warts in Australian women prior to the national vaccination program. Sex Health 2009; 6 178–84.
PubMed |

[7] HPA Centre for Infection. Sexually transmitted infections and young people in the United Kingdom 2008 report. London: Health Protection Agency, HIV and Sexually Transmitted Infections Department Centre for Infections, 2008. Available online at: http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1216022460726 [verified February 2010].

[8] Villa LL,  Costa RL,  Petta CA,  Andrade RP,  Paavonen J,  Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95 1459–66.
CrossRef | PubMed |

[9] Olsson SE,  Villa LL,  Costa RL,  Petta CA,  Andrade RP,  Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25 4931–9.
CrossRef | PubMed |

[10] FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356 1915–27.
CrossRef | PubMed |

[11] Ault KA, FUTURE II Study Group Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369 1861–8.
CrossRef | PubMed |

[12] Harper DM,  Franco EL,  Wheeler CM,  Moscicki AB,  Romanowski B,  Roteli-Martins CM, et al. HPV vaccine study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367 1247–55.
CrossRef | PubMed |

[13] Schwarz TF. Human papillomavirus-16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer. Expert Rev Obstet Gynecol 2007; 2 293–303.
CrossRef |

[14] The GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374 1975–85.
CrossRef | PubMed |

[15] Paavonen J,  Naud P,  Salmerón J,  Wheeler CM,  Chow S-N,  Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374 301–14.
CrossRef | PubMed |

[16] David MP,  Van Herck K,  Hardt K,  Tibladi F,  Dubin G,  Descamps D, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 2009; 115(Suppl 3): S1–6.
CrossRef | PubMed |

[17] Reisinger KS,  Block SL,  Lazcano-Ponce E,  Samakoses R,  Esser MT,  Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26 201–9.
CrossRef | PubMed |

[18] Pedersen C,  Petaja T,  Strauss G,  Rumke HC,  Poder A,  Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40 564–71.
CrossRef | PubMed |

[19] Schwarz TF,  Spaczynski M,  Schneider A,  Wysocki J,  Galaj A,  Perona P, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine 2009; 27 581–7.
CrossRef | PubMed |

[20] Muñoz N,  Manalastas R,  Pitisuttihum P,  Tresukosol D,  Monsonego J,  Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women ages 24–45 years: a randomised, double-blind trial. Lancet 2009; 373 1949–57.
CrossRef | PubMed |

[21] Viscidi RP,  Schiffman M,  Hildesheim A,  Herrero R,  Castle PE,  Bratti MC, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13 324–7.
CrossRef | PubMed |

[22] Grainge MJ,  Seth R,  Guo L,  Neal KR,  Coupland C,  Vryenhoef P, et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis 2005; 11 1680–5.
PubMed |

[23] Bosch FX,  Burchell AN,  Schiffman M,  Giuliano AR,  de Sanjose S,  Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 K1–16.
CrossRef | PubMed |

[24] Garland SM,  Hernandez-Avila M,  Wheeler CM,  Perez G,  Harper DM,  Leodolter S, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356 1928–43.
CrossRef | PubMed |

[25] Food and Drug Administration Center for Biologics Evaluation and Research Office of Vaccines Research and Review, Division of Vaccines and Related Product Applications. Clinical Review of Biologics License Application Supplement STN# 125126/1297.0 – male indication for GARDASIL. Available online at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190977.pdf [accessed 11 February 2010].

[26] Australian of the Year 2006, National Australia Day Council, Old Parliament House, King George Terrace, Parkes ACT 2600, Australia. Available online at: http://www.australianoftheyear.org.au/pages/page58.asp [verified February 2010].

[27] Roughead EE,  Gilbert AL,  Vitry AI. The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy. Health Policy 2008; 88 250–7.
CrossRef | PubMed |

[28] Szarewski A. HPV vaccines: peering through the fog. J Fam Plann Reprod Health Care 2008; 34 207–9.
CrossRef | PubMed |

[29] Einstein MH,  Baron M,  Levin MJ,  Chatterjee A,  Edwards RP,  Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix® and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin 2009; 5 705–19.
CrossRef | PubMed |

[30] Brown DR,  Kjaer S,  Sigurdsson K,  Iversen O-E,  Hernandez-Avila M,  Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199 926–35.
CrossRef | PubMed |

[31] Wheeler CM,  Kjaer SK,  Sigurdsson K,  Iverson O-E,  Hernandez-Avila M,  Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009; 199 936–44.
CrossRef | PubMed |

[32] Harper DN. Current prophylactic HPV vaccines and gynecologic premalignancies. Cur Opin Obstet Gynecol 2009; 21 457–64.
CrossRef |

[33] Pastrana DV,  Buck CB,  Pang YY,  Thompson CD,  Castle PE,  FitzGerald PC, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321 205–16.
CrossRef | PubMed |

[34] Einstein MH,  Baron M,  Levin M,  Chatterjee A,  Carletti I,  Dessy F,  on behalf of the HPV-010 Study Group Comparative evaluation of immunogenicity of two prophylactic human papillomavirus cervical cancer vaccines ESGO, Belgrade, October 2009; Poster No: 102. Int J Gynecol Cancer 2009; 19 894.


[35] Schiller JT,  Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200 166–71.
CrossRef |

[36] Joura EA,  Leodolter S,  Hernandez-Avila M,  Wheeler CM,  Perez G,  Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369 1693–702.
CrossRef |

[37] HPV Information Centre, Summary Report January 2010, p. 27. HPV type specific distribution among women with normal cytology, precancerous lesions and cervical cancer http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/XWX.pdf?CFID=3447676&CFTOKEN=78601863 [verified May 2009].



Rent Article (via Deepdyve) Export Citation Cited By (1)